Dr. Ami Parekh
|
Ami Parekh, MD, JD sets Included Health company’s clinical vision and strategy to deliver value for clients and improve health outcomes for members. She leads the company's clinical team which consists of 1000+ clinicians across primary care, urgent care, behavioral health and navigation as well as the company's provider strategy and relations team and it's clinical strategy & outcomes research team. Previously, she was Chief Medical Officer for Population Health and Clinical Integration at UCSF Health, and also worked at McKinsey. Ami serves on the Blue Cross Blue Shield of Massachusetts board of directors. After Yale Medical School and Yale Law School, she completed her Internal Medicine Residency at Harvard's Brigham and Women's Hospital. She lives in San Francisco with her family.
|
Ann Lee Karlon
|
Ann Lee-Karlon, PhD, is the CEO, President, and Board member of EpiBiologics. She previously served as COO of Altos Labs, where she was instrumental in building the foundation for rapid growth to 500 employees across 3 global sites. Prior to Altos, Ann spent over 18 years at Genentech, most recently as Senior Vice President. During her tenure at Genentech, she led portfolio strategy and operations and had project leadership oversight for over 80 drug development teams from research and development through FDA approval and global launch. She led major corporate partnerships and programs, including Ocrevus for multiple sclerosis and Rituxan in immunology. Before Genentech, Ann served in the new ventures group at Lilly. Ann holds a BS in bioengineering from UC Berkeley, MBA from Stanford University, and PhD in bioengineering from UC San Diego, where she was a National Science Foundation Fellow. Ann was the president and board chair of the Genentech Patient Foundation and president and board chair of the Association for Women in Science, based in Washington, D.C. She is a board member of Eko Health and serves on the Dean’s advisory boards for UC Berkeley and UCSD schools of engineering. Ann was elected Fellow of the American Institute for Medical and Biological Engineering and is a Fellow of the Aspen Institute.
|
Amanda Goltz
|
Amanda Goltz, MPA, is the Director, Industry Partnerships for Stanford Medicine, driving co-creation of novel digital health and technology solutions from research to implementation, across both Stanford Health Care and the School of Medicine. Before joining Stanford, Amanda led two healthcare initiatives at Amazon; the Global Accelerator program for healthcare startups at Amazon Web Services (AWS), and launching Alexa Health and Wellness, the first-ever voice AI experiences for medication refills and management, home care plans, and COVID information. Amanda has held executive roles across the healthcare ecosystem, including at a pharma (BTG, now Boston Scientific), a payer (Aetna), an employer coalition (Pacific Business Group on Health), a state government (California Department of Health and Human Services), and two provider systems (MassGeneralBrigham and New York City Health and Hospital Corporation.) Amanda advises startup companies and VCs globally on innovation in the U.S. healthcare market, as well as technology companies' potential for driving change at scale in the healthcare industry. Amanda has a Master’s in Public Administration in Healthcare Finance and Policy from the Wagner School of Public Service at New York University, and a BA from Columbia College of Columbia University.
|
Stephanie Wisner
Co-Founder & CBO CentiVax |
Stephanie A. Wisner co-founded the biotech start-up, Centivax, where she is now Chief Business Officer. She has also advised multiple biotech start-ups on business and commercialization strategy through her consulting business, BioVenture Advising LLC , and spent several years at ARCH Venture Partners. In 2022, she was named to the Forbes 30 Under 30 list for Healthcare. She completed her MBA at the University of Chicago Booth School of Business, with concentrations in finance, accounting, and entrepreneurship. She received her Bachelor’s Degree in chemistry and chemical biology from Cornell University and was awarded the Einhorn Discovery Research Grant for her independent research on cancer. Her book, Building Backwards to Biotech, was an Amazon #1 New Release in the category of Biotechnology. The book is currently taught as part of bioentrepreneurial programming at multiple top institutions, including Dartmouth College, Cornell University, and others. She is an Entrepreneur-in-Residence as well as a faculty member at Cornell University, Johnson School of Business. While she no longer gets as much time in the lab, she enjoys the travel and continuous learning this career involves. You can reach Stephanie at bioventureadvising.com.
|